Sign In
Buy SILO
$4.19
-0.0600 (-1.41%)
At Close: Jul 31, 2026
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla. , April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmenta
Silo Pharma Rallies After Securing Key Patent Allowance
09:40am, Tuesday, 07'th Apr 2026
Silo said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for the application, which the company has an exclusive license from Columbia University.
Meanwhile, Iran has submitted a 10-point response to the U.S. peace proposals, which a U.S. official described as "maximalist", citing the Iranian state news agency IRNA.
Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know
02:11am, Tuesday, 07'th Apr 2026
Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
04:15pm, Monday, 06'th Apr 2026
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SIL
Contrasting Palvella Therapeutics (NASDAQ:PVLA) & Silo Pharma (NASDAQ:SILO)
01:20am, Saturday, 14'th Mar 2026
Silo Pharma (NASDAQ: SILO - Get Free Report) and Palvella Therapeutics (NASDAQ: PVLA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two
Silo Pharma Announces Share Buyback Program
04:15pm, Monday, 23'rd Feb 2026
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with p
Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
08:28am, Wednesday, 18'th Feb 2026
SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulat
Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update
04:34am, Thursday, 05'th Feb 2026
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 518,127 shares, a drop of 12.
Silo Pharma (NASDAQ:SILO) Stock Price Up 3.6% – Still a Buy?
02:44am, Friday, 23'rd Jan 2026
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) shares traded up 3.6% during trading on Thursday. The stock traded as high as $0.3754 and last traded at $0.3689. 45,852 shares traded hands during m
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
08:05am, Tuesday, 30'th Dec 2025
Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Co
Contrasting Silo Pharma (NASDAQ:SILO) & MannKind (NASDAQ:MNKD)
02:18am, Friday, 21'st Nov 2025
MannKind (NASDAQ: MNKD - Get Free Report) and Silo Pharma (NASDAQ: SILO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies
SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company
Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
08:25am, Wednesday, 29'th Oct 2025
Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo's objective of generating yield while maintainin
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
08:45am, Thursday, 23'rd Oct 2025
Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence before year-end SARASOTA, FL, Oct. 23,
